PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.49%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-15.26%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-50.43%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-43.14%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-43.14%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
5.01%
Share count expansion well above TRVN's 1.61%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.01%
Diluted share count expanding well above TRVN's 1.61%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-30.81%
Negative OCF growth while TRVN is at 9.97%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-30.34%
Negative FCF growth while TRVN is at 10.51%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52488.47%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-16557.44%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-182.36%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-47013.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-7873.57%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-9.65%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
20722.38%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
5960.52%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
359.30%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.39%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-49.71%
We’re deleveraging while TRVN stands at 0.16%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.16%
R&D growth drastically higher vs. TRVN's 9.21%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
23.98%
We expand SG&A while TRVN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.